Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Therefore, at the present time Vertex cannot be accurately valued by trailing earnings. As these one-time costs subside, analysts see Vertex earning $18.78/share in fiscal 2025, with the stock ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $459 from $450 and keeps an Equal ...

Truist Securities increased the price target for Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX), a $121 ...

Try Now>> See Insiders’ Hot Stocks on TipR Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is positive ...

Vertex has doubled down on cell-based therapies ... $1 billion acquisition of Semma in 2019 – because the FDA wanted to see additional data before allowing the dose to be increased.

The new agreement builds on a partnership between the companies in 2015 and will see Vertex cut its share of development expenses from 100% to 60%. Vertex will receive 60% of profits from future ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex works to build markets for new drugs like Casgevy and Journavx.

This extraordinary celestial event will see the sky scattered with seven visible planets in what is known as a great planetary alignment. The eight planets in our solar system orbit the sun in ...